Performance of high-dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose

Juliette V.L. Simons; Reineke Soegiharto; André C. Knulst; Juul M.P.A. van den Reek; Heike Röckmann

doi:10.1016/j.jaip.2024.06.014

Performance of high-dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose

Juliette V.L. Simons^*, Reineke Soegiharto, André C. Knulst, Juul M.P.A. van den Reek, Heike Röckmann

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	3163-3165.e2
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	12
Issue number	11
Early online date	19 Jun 2024
DOIs	https://doi.org/10.1016/j.jaip.2024.06.014
Publication status	Published - Nov 2024

Access to Document

10.1016/j.jaip.2024.06.014Licence: CC BY-NC-ND

PIIS2213219824006378Final published version, 275 KBLicence: CC BY-NC-ND

Cite this

@article{692a9cf03f7b43afa478217d20378a16,

title = "Performance of high-dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose",

author = "Simons, {Juliette V.L.} and Reineke Soegiharto and Knulst, {Andr{\'e} C.} and {van den Reek}, {Juul M.P.A.} and Heike R{\"o}ckmann",

year = "2024",

month = nov,

doi = "10.1016/j.jaip.2024.06.014",

language = "English",

volume = "12",

pages = "3163--3165.e2",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - Performance of high-dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose

AU - Simons, Juliette V.L.

AU - Soegiharto, Reineke

AU - Knulst, André C.

AU - van den Reek, Juul M.P.A.

AU - Röckmann, Heike

PY - 2024/11

Y1 - 2024/11

UR - http://www.scopus.com/inward/record.url?scp=85198204069&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2024.06.014

DO - 10.1016/j.jaip.2024.06.014

M3 - Article

C2 - 38906397

AN - SCOPUS:85198204069

SN - 2213-2198

VL - 12

SP - 3163-3165.e2

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 11

ER -

Performance of high-dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose

Access to Document

Other files and links

Cite this